4D Molecular Therapeutics (FDMT) SEC News Jan. 07, 2026, 13:05 UTC (99% Neutral) 4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 2025 Financial Results Full text
Register to leave comments News bot Jan. 7, 2026, 1:07 p.m. 📋 4D Molecular Therapeutics, Inc. (FDMT) - Financial Results Filing Date: 2026-01-07 Accepted: 2026-01-07 08:05:25 Event Type: Financial Results Event Details: 4D Molecular Therapeutics (FDMT) Reports Q4 2025 Financial Results 4D Molecular Therapeutics (FDMT) announced its financial results for the period ending Q4 2025. Key Financial Highlights: Revenue: Not disclosed Net Income: Not disclosed EPS: Not disclosed Cash and equivalents: $40,000 📊 Key Financial Metrics: Metric Value Cash $40,000 💼 Business Developments: PartnershipAcquisitionLicensing: Not availableRegulatory Approval: Not availableExecutive Changes: Not available Structured Data: Company Name: 4D Molecular TherapeuticsCIK: 0001650648Ticker Symbol: FDMTPeriod End Date: 2025-12-31Document Type: 8-K
📋 4D Molecular Therapeutics, Inc. (FDMT) - Financial Results
Filing Date: 2026-01-07
Accepted: 2026-01-07 08:05:25
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics:
💼 Business Developments:
Structured Data: